Agree with BL’s logic here. I just double check
Post# of 148187
However, I don’t agree with your logic that there’s nothing to license re: mono. There’s very little functional difference between a partnership where an entity helps fund trials along the way for the right to sell the drug later and a licensing deal. In this case, it could be implied in the terms and discussions that a portion of the revenue and/or milestones that CYDY is to receive is due to the need to fund the mono trial, etc. They could negotiate it however they choose.